Placebo response in neuropathic pain after spinal cord injury: a meta-analysis of individual participant data

Background: Understanding factors associated with high placebo responses in clinical trials increases the likelihood of detecting a meaningful treatment effect. The aim of the present study was to identify subject-level factors that contribute to placebo variability in patients with neuropathic pain due to spinal cord injury (SCI).

Methods: Multiple regression analysis of patient data from randomized, double-blind, placebo-controlled trials (duration >4 weeks) involving individuals with SCI was performed. Patient demographics, as well as injury and pain characteristics were examined for their association with changes in pain rating from baseline to the end of the trial (i.e., placebo response). The overall effect of individual predictors was quantified with meta-analysis statistics.

Results: A total of 276 patients with SCI from six studies were included in the analysis. Based on the meta-analysis of subject-level predictors, larger placebo responses were associated with male subjects (β=0.635; standard error [SE]=0.262; p=0.016) and higher baseline pain (β=−0.146; SE=0.073; p=0.044). There were no significant effects for injury characteristics (i.e., severity, level, and time since injury) or pain characteristics (i.e., location and evoked). No significant publication bias was detected.

Conclusion: The current meta-analysis of individual patient data demonstrated the importance of sex and baseline pain intensity on changes in pain ratings in the placebo arm of SCI central neuropathic pain randomized controlled clinical trials. Overall, our findings indicate that placebo responses occur independent of injury characteristics.

Keywords: placebo response, clinical trial, spinal cord injury, neuropathic pain

Introduction

The placebo effect represents a major challenge for the design of clinical trials aimed at relieving chronic pain. The difficulty stems from large changes in pain without an active intervention, which potentially masks meaningful treatment effects. The “placebo problem” is compounded by limited prediction of treatment effects based on preclinical pain models. Understanding factors underlying placebo responses has, as a consequence, emerged as an approach to improve the design and interpretation of chronic pain clinical trial outcomes.

Central neuropathic pain arises because of damage in the central nervous system (CNS), and is common in individuals with multiple sclerosis, stroke, and spinal cord injury (SCI). Interestingly, clinical trials in SCI neuropathic pain report smaller placebo responses relative to other neuropathic pain conditions (e.g., diabetic and HIV neuropathy). This difference raises the possibility that unique factors associated
with central neuropathic pain (e.g., damage in the CNS) contribute to lower placebo responses. A recent meta-analysis identified that longer pain duration and greater between-subject baseline pain variability were associated with a decreased placebo response in patients with central neuropathic pain.12

Meta-analyses of published studies are often used to pool effect sizes.13,14 As an extension of meta-analysis, meta-regression is commonly performed to examine the relationship between effect size and study (e.g., sample size and allocation concealment) and patient-level variables (e.g., age and sex). Conventional meta-regression of pooled study data suffers from major limitations. The most substantial concern is that a correlation observed at the study level may be inversely correlated at the patient level (i.e., ecological fallacy). In addition, study-level meta-regression has limited sensitivity to detect important patient-level factors related to the outcome. To accurately derive these relationships, analysis of individual patient data (IPD) is needed.15–19 Meta-analyses of IPD are considered the gold standard for systematic reviews.16,20

To address factors associated with placebo responses in neuropathic pain, we performed a meta-analysis of patient-level data pertaining to six placebo-controlled randomized trials (RCTs) conducted in the field of SCI. Our primary aim was to examine the effect of subject-level predictors on placebo responses. Specifically, we tested the hypothesis that patient demographics, injury, and pain characteristics contribute to the variability of placebo responses in individuals with neuropathic pain after SCI.

Materials and methods
This study was approved by the University of British Columbia’s Clinical Research Ethics Board (H15-00475).

Study selection: search, inclusion, and exclusion criteria
A systematic literature search of English-language articles was performed using PubMed between September 2015 and January 2016. Search terms included “placebo”, “spinal cord injury”, and “pain”. Hand searching was also performed, reviewing reference lists of relevant trials and comprehensive review articles. Additional search terms and combinations were considered to further identify relevant studies (e.g., “neuropathic”, “central pain”). We included randomized, placebo-controlled, parallel- or crossover-designed studies for which IPD were available. Only datasets from pharmacologic studies using inert placebos and treatment durations longer than 4 weeks were included in this analysis. Case studies and open-label clinical trials (i.e., those with no placebo condition) were excluded. Based on this search, corresponding authors were contacted by email to obtain the patient-level data. Contact was also made by email for industry-sponsored studies.

Predictor variables
The following patient-level information was obtained for all subjects undergoing placebo treatment: age, sex, injury characteristics (i.e., level and severity of injury, time since injury), and pain characteristics (i.e., baseline and post-placebo pain intensity, quality of pain (i.e., evoked). The level and severity of injury were classified using the International Standards for the Neurological Classification of SCI.21 Level of injury was dichotomized as thoracic or cervical. Completeness of injury was determined according to the American Spinal Injury Association Impairment Scale (AIS) grades. Injury completeness was dichotomized as “complete” (i.e., AIS-A subjects, with no sensory or motor function caudal to the level of injury) or incomplete injuries (i.e., AIS-B to D subjects, with motor and/or sensory sparing).21

Statistical analysis
R Statistical Software version 2.15.3 was used for all analyses. Placebo response (dependent variable) was defined as the overall change in rating of the neuropathic pain intensity (i.e., based on 0–10 numeric rating scale) from baseline to the end of the study or the last measurement. As there is a known trial-design effect on placebo response12 and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. A priori studies from the same investigators using similar experimental design (e.g., crossover study) were pooled to increase sample size.22,23

In step 1, multivariable regression statistics were used to calculate effect sizes (beta coefficient) and a measure of variance (standard error [SE]). Subject characteristics (age and sex), injury characteristics (plegia, completeness, and duration since injury), and pain characteristics (baseline pain intensity rating) were modeled separately. In an exploratory analysis, the effects of evoked pain (i.e., allodynia) and location of pain (i.e., at-level, below-level, or both) on the placebo response were independently examined.22–25

Step 2 of our analysis examined the overall effect size of subject, injury, and pain characteristics across studies (i.e., a pooled effect size). The R package metafor was used to
perform a meta-analysis on the regression coefficients derived from bivariable and multivariable regression models. Forest plots were produced to visualize the results from the random-effect models (R function: forest). Funnel plots were used to assess publication bias (R function: funnel). To assess publication bias by examining asymmetry in the funnel plots, the Egger test was used (R function: regtest).27

Results
Study selection and characteristics
The results of the study selection are presented in Figure 1. A total of six placebo-controlled studies met the inclusion criteria and were thus included in the analysis.22–24,28–30 The data of 276 chronic SCI patients were acquired from the authors of the original studies22–24,30 or industry sponsors.28,29 Six patients from one study24 had to be excluded as not all of the information required for the present study was available in the dataset. Table 1 provides a detailed overview of all the studies included. Ten studies were excluded from the analysis because of the use of an active placebo (n=2),25,31 a treatment duration <4 weeks (n=7),25,31–39 or no access to the IPD (n=1).39

Placebo response
Figure 2A illustrates the placebo responses for all studies reviewed (β=−0.622; SE=0.39; p=0.115). Overall, there was no significant placebo response. No significant publication bias was detected by Egger’s regression test for funnel plot asymmetry (p=0.674; Figure 2B).

Multivariable regression analyses
All results from the multivariable regression analyses are summarized in Table 2.

Meta-regression: patient, injury, and pain characteristics
Based on meta-regression statistics of individual patient-level data, sex (β=0.635; SE=0.262; p=0.016; Figure 3A) and baseline pain intensity rating (β=−0.146; SE=0.073; p=0.044; Figure 4) were associated with placebo responses. Males and higher baseline pain intensity ratings were associated with larger placebo responses. No significant publication bias was detected by Egger’s regression test for funnel plot asymmetry (sex: p=0.669, baseline pain: p=0.361, placebo response: p=0.673). Age (Figure 3B), injury severity (Figure 5A), level (Figure 5B), and duration (Figure 5C) did not significantly predict placebo responses.

Planned exploratory analysis
In two available trials, evoked pain (β=0.345; SE=1.086; p=0.751; Figure 6A) was not associated with placebo responses. Placebo responses were higher in individuals with below-level compared with below- and at-level neuropathic pain (i.e., both) (Figure 6B). However, this effect was not observed after adjusting for baseline pain (β=0.065; SE=0.481; p=0.893; Figure 6C).

Discussion
Our study examined factors contributing to variable placebo responses in individuals with SCI neuropathic pain. For that purpose, IPD (n=276) derived from six randomized clinical trials were examined. Based on a patient-level meta-approach, sex and baseline pain intensity ratings were the only variables significantly associated with placebo responses. There was a trend toward larger placebo responses in individuals with incomplete injuries (versus complete); however, this effect was not consistent across examined trials. Other neuropathic pain, injury, or subject characteristics were not related to

**Table 1.** Flow diagram for the selection of randomized placebo-controlled trials. **Abbreviation:** IPD, individual patient data.
Table 1 Details of reviewed studies

<table>
<thead>
<tr>
<th>Study details</th>
<th>Study 1</th>
<th>Study 2</th>
<th>Study 3</th>
<th>Study 4</th>
<th>Study 5</th>
<th>Study 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td>Crossover</td>
<td>Crossover</td>
<td>Parallel</td>
<td>Parallel</td>
<td>Parallel</td>
<td>Parallel</td>
</tr>
<tr>
<td>Intervention</td>
<td>Levetiracetam</td>
<td>Lamotrigine</td>
<td>Pregabalin</td>
<td>Pregabalin</td>
<td>Venlafaxine XR</td>
<td>Palmitoylethanolamide</td>
</tr>
<tr>
<td>Duration of placebo, days</td>
<td>Mean (SD)</td>
<td>29.4 (11.6)</td>
<td>61.9 (30.5)</td>
<td>171.6 (9.6)</td>
<td>81.8 (9.4)</td>
<td>82.3 (22.3)</td>
</tr>
<tr>
<td>Subject characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>18</td>
<td>12</td>
<td>67</td>
<td>106</td>
<td>39</td>
<td>34</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>15 (83.3)</td>
<td>10 (83.3)</td>
<td>54 (80.6)</td>
<td>91 (85.8)</td>
<td>33 (84.6)</td>
<td>29 (85.3)</td>
</tr>
<tr>
<td>Female</td>
<td>3 (16.7)</td>
<td>2 (16.7)</td>
<td>13 (19.4)</td>
<td>15 (14.2)</td>
<td>6 (15.4)</td>
<td>5 (14.7)</td>
</tr>
<tr>
<td>Age, years</td>
<td>Mean (SD)</td>
<td>56.6 (10.9)</td>
<td>41.5 (10.7)</td>
<td>49.8 (14.2)</td>
<td>45.3 (14.0)</td>
<td>42.7 (11.1)</td>
</tr>
<tr>
<td>Injury characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASIA Impairment Scaleb, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A: Complete</td>
<td>6 (33.3)</td>
<td>5 (41.7)</td>
<td>34 (50.7)</td>
<td>57 (53.8)</td>
<td>23 (59.0)</td>
<td>10 (29.4)</td>
</tr>
<tr>
<td>B: Incomplete</td>
<td>1 (5.6)</td>
<td>1 (8.3)</td>
<td>7 (10.4)</td>
<td>10 (9.4)</td>
<td>6 (15.4)</td>
<td>3 (8.8)</td>
</tr>
<tr>
<td>C: Incomplete</td>
<td>1 (5.6)</td>
<td>2 (16.6)</td>
<td>7 (10.4)</td>
<td>7 (6.6)</td>
<td>5 (12.8)</td>
<td>9 (26.5)</td>
</tr>
<tr>
<td>D: Incomplete</td>
<td>10 (55.6)</td>
<td>4 (33.3)</td>
<td>19 (28.4)</td>
<td>32 (30.2)</td>
<td>5 (12.8)</td>
<td>12 (35.3)</td>
</tr>
<tr>
<td>Cause of SCI, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Violence (e.g., gunshot)</td>
<td>–</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>8 (7.5)</td>
<td>14 (35.9)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Accident (e.g., fall, vehicular)</td>
<td>–</td>
<td>8 (66.7)</td>
<td>59 (88.1)</td>
<td>81 (76.5)</td>
<td>21 (53.8)</td>
<td>22 (64.7)</td>
</tr>
<tr>
<td>Other</td>
<td>–</td>
<td>4 (33.3)</td>
<td>8 (11.9)</td>
<td>17 (16)</td>
<td>4 (10.3)</td>
<td>12 (35.3)</td>
</tr>
<tr>
<td>Time since injury, years</td>
<td>Mean (SD)</td>
<td>4.6 (4.1)</td>
<td>13.0 (9.5)</td>
<td>10.4 (9.8)</td>
<td>10.6 (10.3)</td>
<td>16.7 (13.0)</td>
</tr>
<tr>
<td>Plegia, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraplegia</td>
<td>10 (55.6)</td>
<td>7 (58.3)</td>
<td>38 (56.7)</td>
<td>56 (52.8)</td>
<td>15 (38.5)</td>
<td>20 (58.8)</td>
</tr>
<tr>
<td>Tetraplegia</td>
<td>18 (44.4)</td>
<td>5 (41.7)</td>
<td>29 (43.3)</td>
<td>50 (47.2)</td>
<td>24 (61.5)</td>
<td>14 (41.2)</td>
</tr>
<tr>
<td>Pain characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline pain score</td>
<td>Mean (SD)c</td>
<td>6.8 (1.3)</td>
<td>5.3 (1.7)</td>
<td>6.7 (1.4)</td>
<td>6.5 (1.4)</td>
<td>7.0 (1.8)</td>
</tr>
<tr>
<td>Location, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At level of SCI</td>
<td>1 (5.6)</td>
<td>2 (16.7)</td>
<td>–</td>
<td>25 (23.7)</td>
<td>–</td>
<td>7 (20.6)</td>
</tr>
<tr>
<td>Below level of SCI</td>
<td>6 (33.3)</td>
<td>5 (41.7)</td>
<td>–</td>
<td>53 (50.0)</td>
<td>–</td>
<td>14 (41.2)</td>
</tr>
<tr>
<td>Both</td>
<td>11 (61.1)</td>
<td>5 (41.7)</td>
<td>–</td>
<td>28 (26.3)</td>
<td>–</td>
<td>13 (38.2)</td>
</tr>
</tbody>
</table>

Notes: As there is a known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. aAmerican Spinal Injury Association (ASIA) Impairment Scale: A, no sensory or motor function is preserved; B, sensory function is preserved below the level of the injury, but there is no motor function; C, sensory and motor functions are preserved below the neurologic level, and more than half of the key muscles below the neurologic level have a muscle grade of <3; D, sensory and motor functions are preserved below the neurologic level, and at least half of the key muscles below the neurologic level have a muscle grade of >3. cBaseline pain levels were assessed using a 11-point Numeric Rating Scale (0 = no pain, 10 = worst possible pain).

Abbreviation: SCI, spinal cord injury.

placebo responses. Overall, placebo responses among individuals with neuropathic pain due to SCI were small and difficult to predict at the subject level.

Low placebo response hallmarks SCI clinical trials

According to our meta-analysis, individuals with SCI and neuropathic pain have no significant placebo response in clinical trials testing pharmacologic interventions lasting 4 weeks or longer. This finding is in agreement with the small effect we previously reported,12 but is in stark contrast to the majority of other chronic pain conditions.40–46 Emerging clinical trial data have further substantiated our observation of limited placebo response in SCI patients. In a recent trial demonstrating the efficacy of botulinum toxin type A (BTXA), fewer than 10% of SCI patients administered saline achieved a meaningful reduction in pain (i.e., >30%).47 Comparatively, approximately almost half of the patients with myofascial pain in a similarly designed BTXA clinical trial (i.e., also 4 weeks in duration, parallel design) responded (i.e., >30% reduction in pain) to the administration of saline.48 In a BTXA clinical trial, large placebo responses are expected, given the invasiveness of the intervention compared with conventional pharmacologic studies.49,50
While there was no overall significant placebo response, three trials demonstrated average reductions in pain intensity ratings with placebo. The largest placebo response was reported in a recent trial conducted in the USA. Comparatively, the most recent trial conducted in Europe reported no discernible placebo response. Collectively, these observations correspond with findings that indicate that placebo responses are increasing in American neuropathic pain clinical trials. However, the high placebo response in the American trial should be interpreted with caution as the study was focused on depression, which may confound the results; the placebo response rate in depression consistently falls between 20% and 40% (e.g., improvement on the 29-item modified Hamilton Depression Scale).

The presence of damage in the CNS represents the most distinguishing physiologic/anatomical feature that could explain small placebo responses in individuals with SCI. In principle, damage in the spinal cord disrupts normal physiology involved in generating placebo analgesia, thereby reducing the capacity to experience placebo response. Our subject-level meta-analysis indicates a trend to this effect, namely, that individuals with more complete injuries tended to exhibit smaller placebo responses than individuals with incomplete injuries (Figure 7). Comparatively, level of injury (i.e., para versus tetra) had no discernible impact on placebo responses. The impact of injury severity on individual placebo responses was not, however, consistent enough across trials to yield an overall effect. A variable effect of injury severity on placebo responses may be related to a number of factors, including that a clinical measure of damage in the spinal cord (i.e., AIS grades) is insufficient to characterize the extent of pathology in spinal pathways involved in placebo analgesia. From a pragmatic perspective, injury completeness may only have a subtle effect, while other factors play a much larger role in placebo (e.g., expectation).

**Predictors of placebo response**

Reductions in pain were predicted by baseline ratings, insofar as patients with higher ratings demonstrated larger placebo responses. This is consistent with the notion that enrollment in clinical trials occurs when pain intensity is at its peak, and that a follow-up measurement is biased to decrease (i.e., regression toward the mean). Our observations also indicate that male patients have larger placebo responses than females. With regard to sex-related differences, other studies have reported similar observations or no effect of sex. Caution interpreting the effect of sex is warranted on the basis that the vast majority of subjects examined herein were male, consistent with the typical demographics of SCI.

If not related to damage in the spinal cord, what factors unique to SCI explain markedly low placebo responses (i.e., no significant response across all trials)? SCI neuropathic pain is commonly regarded as a chronic condition refractory to treatment. This, in turn, could decrease expectation of benefit and drive lower placebo responses. The unique complexities of neuropathic pain, including that pain symptoms arise from other secondary health complications (e.g., infections, spasticity, and pressure ulcers to name a few), may also contribute to low placebo responses. Finally, all of the IPD included in our meta-analysis are all from preapproval trials.

---

**Table:**

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Siddall et al, 2006</td>
<td>–0.45 (–0.79, –0.11)</td>
</tr>
<tr>
<td>Cardenas et al, 2013</td>
<td>–1.21 (–1.55, –0.86)</td>
</tr>
<tr>
<td>Richards et al, 2015</td>
<td>–1.69 (–2.40, –0.98)</td>
</tr>
<tr>
<td>Andresen et al, 2016</td>
<td>0.67 (0.19, 1.16)</td>
</tr>
<tr>
<td>Random effects model</td>
<td>–0.62 (–1.40, 0.15)</td>
</tr>
</tbody>
</table>

**Figure 2:** Change in pain intensity in the placebo group for all studies. Notes: A negative mean difference indicates a reduction in pain score after placebo treatment. Funnel plot: standard error against mean change in pain intensity for the placebo group for all studies. As there is a known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. To increase the sample size these two studies were pooled.
### Table 2 Prediction of change in pain rating (placebo response)

<table>
<thead>
<tr>
<th>Subject characteristics</th>
<th>Injury characteristics</th>
<th>Pain characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Constant</td>
<td>Sex</td>
</tr>
<tr>
<td>Study 1 and 2 pooled(^a)</td>
<td>β</td>
<td>2.263</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>(−5.193, −0.668)</td>
</tr>
<tr>
<td></td>
<td>SE</td>
<td>1.428</td>
</tr>
<tr>
<td></td>
<td>β-p-value</td>
<td>0.125</td>
</tr>
<tr>
<td>Study 3 (Siddall et al(^{29}) 2006)</td>
<td>β</td>
<td>−1.384</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>(−3.050, −0.281)</td>
</tr>
<tr>
<td></td>
<td>SE</td>
<td>0.834</td>
</tr>
<tr>
<td></td>
<td>β-p-value</td>
<td>0.102</td>
</tr>
<tr>
<td>Study 4 (Cardenas et al(^{28}) 2013)</td>
<td>β</td>
<td>−2.516</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>(−4.035, −0.997)</td>
</tr>
<tr>
<td></td>
<td>SE</td>
<td>0.766</td>
</tr>
<tr>
<td></td>
<td>β-p-value</td>
<td>0.001</td>
</tr>
<tr>
<td>Study 5 (Richards et al(^{24}) 2015)</td>
<td>β</td>
<td>−0.396</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>(−3.594, −2.801)</td>
</tr>
<tr>
<td></td>
<td>SE</td>
<td>1.578</td>
</tr>
<tr>
<td></td>
<td>β-p-value</td>
<td>0.803</td>
</tr>
<tr>
<td>Study 6 (Andresen et al(^{30}) 2016)</td>
<td>β</td>
<td>0.222</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>(−2.525, −2.970)</td>
</tr>
<tr>
<td></td>
<td>SE</td>
<td>1.347</td>
</tr>
<tr>
<td></td>
<td>β-p-value</td>
<td>0.870</td>
</tr>
</tbody>
</table>

**Notes:**\(^a\)Finnerup 2002 and Finnerup 2009: crossover designed studies.\(^\text{22,23}\) As there is a known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. To increase the sample size these two studies were pooled.\(^b\)Categories: tetra- or paraplegia, reference.\(^c\)Complete: AIS A and B, incomplete: AIS C and D.

**Abbreviations:** AIS, Association Impairment Scale; SCI, spinal cord injury; SE, standard error.
Figure 3 Effect of patients' characteristics on the placebo response.

Notes: (A) Age had no modulatory effect on the placebo response. (B) There was a significant main effect of sex. That is, being male was associated with higher placebo response. A negative mean difference indicates a reduction in pain score after placebo treatment. *Finnerup 2002 and Finnerup 2009: 22, 23 cross-over designed studies. As there is a known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. To increase the sample size these two studies were pooled.

Figure 4 Effect of baseline pain intensity and duration of placebo treatment.

Notes: Higher baseline pain ratings at baseline were associated with greater placebo responses. A negative mean difference indicates a reduction in pain score after placebo treatment. *Finnerup 2002 and Finnerup 2009: 22, 23 cross-over designed studies. As there is a known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. To increase the sample size these two studies were pooled.
(i.e., none were performed after a drug had been approved for use in SCI neuropathic pain). Larger responses are associated with postapproval trials.72 Future studies trialing pregabalin (i.e., a drug now approved for use in SCI neuropathic pain) could expect larger placebo responses than reported here.

**Figure 5** Effect of injury characteristics on the placebo response.

**Notes:** The placebo response was not affected by (A) injury completeness, (B) type of plegia (i.e., para- or tetraplegia), and (C) duration of spinal cord injury (SCI). A negative mean difference indicates a reduction in pain score after placebo treatment. *Finnerup 2002 and Finnerup 2009: 22,23 Cross-over designed studies. As there is a known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. To increase the sample size these two studies were pooled.

**Abbreviation:** SCI, spinal cord injury.

**Limitations of the study**

There are some limitations of our analysis. The low number of trials limits the results of our IPD meta-analysis. Despite many advantages compared to conventional group-level meta-analyses,15 individual patient-level meta-analysis will remain limited.
Figure 6 Effect evoked pain and pain location of pain (i.e., at level, below level, or both) on the placebo response.

Notes: A negative mean difference indicates a reduction in pain score after placebo treatment. (A) The presence of evoked pain had no modulatory effect on the placebo response. (B) No difference in placebo response was detected between patients with at-level pain and patients with below level pain or both. Patients with below pain exhibited higher placebo responses compared to those who had at- and below level pain (i.e., both). (C) However, this effect of location was diminished when adjusting for baseline pain rating. Thus, the effect was only related to the baseline pain being higher. *Finnerup 2002 and Finnerup 2009: 22,23 Cross-over designed studies. As there is a known trial-design effect on placebo response and to enable direct comparison with the parallel-designed studies, only patients who received placebo in the first arm were included for the analysis. To increase the sample size these two studies were pooled.

Abbreviation: RE, random effects.
Conclusion

Our meta-analysis of IPD demonstrates that low placebo responses are a hallmark of neuropathic pain in RCTs of individuals with chronic SCI. Contrasting the hypothesis that disease-specific factors contribute to lower placebo responses, injury and pain characteristics were not predictive of changes in pain rating. All identified predictors – baseline pain and sex – are not disease-specific and, thus, poorly explain a reduced capacity to report placebo. These factors, however, still remain crucial to consider when designing clinical trials.

Acknowledgments

Data for this research were provided by Pfizer’s Clinical Trial Data Request Program (Study ID# W1205957). Pfizer had no role in the study design, data collection, statistical analysis, interpretation, or writing of the manuscript. The corresponding author was responsible for the content of the manuscript and the decision to submit for publication. CRJ is supported by postdoctoral research fellowships of the International Foundation for Research in Paraplegia (IRP), the Swiss National Science Foundation, and Craig H. Neilson Foundation. FMW is supported by a University of British Columbia 4-Year Research Fellowship. CM is supported by a salary award from Fonds de recherché Québec – Santé (FRQS). JJC is supported by the Branco Weiss Fellowship – Society in Science and by the Michael Smith Foundation for Health Research (MSFHR). JLKK is a MSFHR and Rick Hansen Institute Scholar, and is also supported by Wings For Life, IRP, and the Canadian Institutes of Health Research.

Disclosure

The authors report no conflicts of interest in this work.

References


